NCT05642468View on ClinicalTrials.gov

Safety and Tolerability of A3907 in Primary Sclerosing Cholangitis

PHASE2CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

January 9, 2023

Primary Completion Date

July 10, 2025

Study Completion Date

July 10, 2025

Conditions
Primary Sclerosing Cholangitis
Interventions
DRUG

Ritivixibat

10mg tablet A3907 administered orally

Trial Locations (8)

8036

Hospital Clinic de Barcelona, Barcelona

20900

ASST di Monza - Azienda Ospedaliera San Gerardo, Monza

35128

Azienda Ospedale Università Padova, Padua

75012

Hopital Saint Antoine, Paris

Unknown

ASST Grande Ospedale Metropolitano Niguarda, Milan

Centrum Medyczne INTER-MED, Częstochowa

Uniwersyteckie Centrum Kliniczne im. Prof. Kornela Gibinskiego, Katowice

ID Clinic Arkadiusz Pisula, Mysłowice

All Listed Sponsors
lead

Albireo, an Ipsen Company

INDUSTRY